Drug Trial Radar · NCT04510194
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,323
Actual
Start
Jan 1, 2021
Primary completion
Dec 14, 2022
Study completion Dec 14, 2022
Sponsor
- Lead sponsor
- University of MinnesotaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- UnitedHealth Group; Northwestern University; Hennepin County Medical Center, Minneapolis; University of Colorado, Denver; Olive View-UCLA Education & Research Institute
- First posted
- Aug 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1. The purpose of this trial is to conduct a 2x3 factorial randomized trials, which efficiently allows the parallel conduct of three randomized trials to understand whether metformin, ivermectin, or fluvoxamine, is superior to placebo for preventing Covid-19 disease progression in non-hospitalized adults with SARS- CoV-2 infection. 2. To understand if the active treatment arms are superior to placebo in improving viral load, serologic markers associated with Covid-19, and gut microbiome in non-hospitalized adults with SARS-CoV-2 infection. 3. To understand if any of the active treatment arms prevent long-covid syndrome, PASC (post-acute sequelae of SARS-CoV-2 infection).
Conditions
- Covid19
- SARS-CoV Infection
Interventions
MetforminDrug
Metformin; immediate release formation; 500mg on Day 1; 500mg BID on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.
PlaceboDrug
placebo; appearance and size are exact matching to the three study drugs.
FluvoxamineDrug
An antidepressant, administered 50mg per day on Day 1; then 50mg twice-daily for Day 2 through Day 14
IvermectinDrug
An anti-parasitic medication administered as 390mcg/kg to 470mcg/kg per day for 3 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Progression to Severe CovidTime frame: 14 Days
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Olive View UCLA Medical Center
Sylmar, California
University of Colorado Denver; Department of Medicine; Anschutz Health and Wellness Center
Aurora, Colorado
New West Physicians
Golden, Colorado
Northwestern University Feinberg School of Medicine
Chicago, Illinois
American Health Network of Indiana
Greenfield, Indiana
Hennepin County Medical Center
Minneapolis, Minnesota
University of Minnesota
Minneapolis, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.